Technology Area: Diagnostics
264 Results for 'Diagnostics'
- Technologies (29)
- Collaborations (4)
- Team (0)
- News (175)
- Pages (0)
- Multimedia (56)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 29
-
Instrument-Free Molecular Diagnostics
A synthetic biology-based molecular diagnostics platform that enables the creation of low-cost, highly accurate tests for non-clinical settings. -
Crisscross Nanoseed Detection: Nanotechnology-Powered Infectious Disease Diagnostics
This nanotech-based diagnostic platform uses a unique nucleation mechanism that assembles a DNA "nanoseed" in the presence of a pathogen-derived biomarker that then is amplified within 15 minutes to create a signal for easy detection. It is highly robust, and cost-effective, and can be adapted to detect a variety of biomarkers. -
Paper-Based Diagnostics
With the imminent threat of new pandemics and frequent disease outbreaks exemplified by the recent Ebola and Zika epidemics, there is a growing need for low-cost, easily deployable and simple-to-use diagnostic tools. The Wyss Institute has developed paper-based synthetic gene networks as a next generation diagnostic technology for use in global healthcare crises and patient... -
eRapid: Multiplexed Electrochemical Sensors for Fast, Accurate, Portable Diagnostics
Handheld electrochemical sensors have revolutionized at-home medical testing for diabetics, but they have not yet been successfully applied to diagnosing other conditions. These sensors are based on the activity of an enzyme, and there are only a limited number of enzymes that can be used to detect biomarkers of human disease. An alternative, much more... -
DNA Nanoswitches: “Lab-on-a-Molecule” Drug Discovery
The Lab-on-a-Molecule platform leverages the Wyss Institute’s DNA nanotechnology technology for the high-throughput, low-cost screening of a wide range of chemical and biologic compounds to enable the discovery of first-in-class therapeutics for various conditions. -
Extracellular Vesicles for Biomarker Detection
A non-invasive method to identify biomarkers of disease across cell types and develop diagnostics and monitoring systems.
Collaborations 4
-
Brigham-Wyss DxA
The Wyss DxA's clinical partners from Brigham and Women’s Hospital identify the most pressing unmet diagnostic needs, provide access to high-quality patient samples for our Biomarker Discovery Laboratory (BDL) and Brigham-Wyss DxA collaborators, and provide invaluable feedback and guidance on the engineering and validation of cost-effective, sensitive, and specific diagnostic tests. -
Biomarker Discovery Laboratory (BDL)
Bridging the diagnostic gap from biomarker discovery to market-ready test kits and instruments through cutting-edge technology development and clinical collaboration. -
Wyss DxA Industrial Participant Program
As the industry-facing component of the Wyss Diagnostics Accelerator, the Industrial Participant Program is a collaboration hub between healthcare testing companies and the scientific and clinical community within the Wyss ecosystem that seeks to compress the timeframe for bringing new, high-impact, diagnostic technologies to market. -
Wyss Diagnostics Accelerator (DxA)
An initiative to enable the fast creation of diagnostic technologies to solve high-value clinical problems through deep collaborations driven by unmet diagnostic needs.
News 175
Multimedia 56
-
Video/AnimationInnovating Diagnostics to Improve Clinical Care and Patient OutcomesGuest speaker, Sarah-Beth Perullo, shares the immense difficulty she faced in obtaining a diagnosis for her mysterious symptoms. Her story is a sobering reminder of how frequent patient symptoms are dismissed in the medical field. Credit: Wyss Institute at Harvard University -
Video/AnimationWorld of OMICs w/ David Walt & Mike Snyder – BIOS RoundtableThis is a roundtable discussion on the world of OMICs with Wyss Core Faculty member David Walt and Mike Snyder of Stanford University presented by BIOS. David Walt is a Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard Medical School, a Professor of Pathology at Brigham and Women’s Hospital, a Core Faculty member at... -
Video/AnimationHow can we restore mobility to the sick and injured?Researchers at the Wyss Institute are working to improve treatment outcomes for patients suffering from reduced mobility. This video focuses on two platform technologies that could improve the quality of life for these patients: stochastic resonance and wearable soft robotics. Credit: Wyss Institute at Harvard University -
Video/AnimationHow can we get diagnostics to patients faster?The Wyss Diagnostics Accelerator (DxA) is an initiative to enable the fast creation of diagnostic technologies to solve high-value clinical problems through deep collaborations driven by unmet diagnostic needs. Credit: Wyss Institute at Harvard University -
Video/AnimationReimagine the World – Volume 2 – Diagnostics AcceleratorTwo clinicians collaborating with the Wyss Diagnostics Accelerator (DxA), Lise Johnson and Craig Hersh, as well as two members of the Wyss DxA Industrial Partnership Program, Nell Meosky Luo and Andy Levin, share how they would Reimagine the World and the personal stories that fuel their passion for the work they are doing. Credit: Wyss... -
Video/AnimationWyss Diagnostics Accelerator – The Industrial Participant ProgramThe Industrial Participant Program (IPP) is a collaboration hub between healthcare testing companies and the scientific and clinical community within the Wyss ecosystem, driven by the Wyss Diagnostics Accelerator (DxA). Members of the IPP share the common goal of fast-tracking diagnostic technologies to meet unmet, critical needs. Credit: Wyss Institute at Harvard University